Cancer therapy » GMBP322, 5 ECTS, 40 hours (in english)

Master Biomed M2 CDC- Cancer
UE « Cancer therapy » GMBP322, 5 ECTS, 40 hours (in english)
Coordonnateurs : A Evrard, MA Poul, W Jacot, C Bourgier, L Le Cam
november 3rd to november 14th, 2014 (to be confirmed)
Aims
of
the
course:
Increased
understanding
of
cancer
biology
has
allowed
the
first
successful
cancer
targeted
therapies
based
on
the
knowledge
of
specific
molecular
targets.
The
identification
of
specific
cancer
subgroups,
associated
with
known
targets
or
drug
susceptibility
profiles
allows
a
more
efficient
selection
of
anticancer
treatment.
At
the
same
time,
a
better
understanding
of
the
pharmacokinetic,
pharmacodynamic
and
pharmacogenomic
aspects
of
cancer
cells’
drug
resistance
and
excessive
drug
toxicities
should
lead
to
an
improved
efficacy
/
toxicity
ratio
in
cancer
treatment.
The
course
"Principles
of
cancer
biology"
is
an
integral
part
of
the
"CDC‐Cancer
Biology
Program"
within
the
Master
BioMed
of
Montpellier
University.
The
goal
of
this
course
is
to
provide
a
broad
understanding
of
the
various
aspects
of
cancer
cells
sensitivity
/
resistance
to
cancer
treatments,
from
the
molecular
targets
of
anti‐
cancer
agents,
targeting
the
cancer
cells
themselves
or
cancer
microenvironment,
to
the
individual
modulation
of
cancer
drugs
response
and
toxicities.
The
course
will
review
chemotherapy,
targeted
therapies,
immunotherapy
and
radiotherapy
approaches
in
cancer.
It
represents
an
ideal
complement
to
the
more
fundamental
courses
on
“Cell
Fate
and
Plasticity”
and
“Cancer
Biology”.
Together,
the
Master
2
Program
in
Cancer
Biology
will
provide
students
with
a
unique
opportunity
to
explore
the
scientific
rationale
for
anticancer
therapies
in
a
very
competitive
scientific
and
medical
environment.
The
students
will
acquire
the
necessary
knowledge
to
enable
them
to
carry
out
original
research
in
the
ever
growing
field
of
cancer
biology.
In
addition,
during
the
Pre‐clinical
models
practical
sessions,
experienced
experts
of
the
field
will
illustrate
how
human
cancer
can
be
modeled
in
the
mouse,
showing
the
latest
technological
developments
based
on
genetically
engineered
mouse
models
as
well
as
humanized
primary
xenograft
models.
Teaching
will
include
theoretical
description
of
the
models
and
associated
technologies,
followed
by
practical
training
sessions
that
will
illustrate
the
use
of
non‐invasive
small
animal
imaging
techniques
as
well
as
histological
analyses.
Part
I
:
Clinical
basis
of
cancer
and
cancer
therapy
(5
h)
W.
Jacot
• Cancerous
disease
history:
from
detection
to
treatment
(epidemiology,
risk
factors..)
(W.
Jacot)
• Pivotal
role
of
anatomapathology
in
diagnosis
and
prognosis
of
cancer
• Clinical
trial
methodology
in
cancerology
(D.
Tosi)
Part
II
:
Chemotherapy,
hormonotherapy
and
targeted
therapies
(9
h)
A.
Evrard
• Basis
and
principles
of
chemotherapy
(N.
Houédé)
• Targeted
therapy
:
from
hormonotherapy
to
small
molecules
inhibitors
of
tyrosine
kinase
(S.
Roche,
JP
Brouillet)
• Pharmacodynamics
aspects
(targets,
signal
transduction
pathways)
of
drug
resistance
(C
Gongora)
• Pharmacogenomics
and
pharmacokinetics
determinants
of
drug
response
and
toxicity
(J.
Ciccolini,
A.
Evrard)
• Cancer
stem
cells
and
drug
response
(JM
Pascussi)
• Improving
drug
delivery
to
the
tumor:
nanoparticles
and
tumor
targeting
(F.
Gattacceca)
Part
III
:
Immunotherapy
(8
h)
MA
Poul
•
•
•
•
•
Immune
response
against
cancer
and
tumor
microenvironnement
(MA
Poul)
Antibody
based‐immunotherapy
against
cancer,
nanobodies
(MA
Poul
or
G
Cartron)
NK
and
T‐cell
based
cancer
immunotherapy
(Naomi
Tayor/Valérie
Dardalhon)
Dendritic
cells
and
anti‐cancer
vaccination
(Franck
Mennechet)
Antibody
Drug
Conjugates
(ADC),
the
best
of
two
world
?
(Bruno
Robert)
Part
IV
:
Radiobiology
and
radiotherapy
(7
h)
C
Bourgier
• Radiobiology
:
physics
and
chemistry
of
radiation
absorption,
modes
of
cell
death
and
cell‐survival
curves
(C
Bourgier)
• Radiobiology
:
DNA
damage,
DNA
repair,
Cell
signaling
(A
Constantinou)
• Radiobiology:
time,
dose,
fractionation,
repopulation,
angiogenesis
(D
Azria)
• Radiosensitizers
and
radioprotector
(C
Bourgier;
Muriel
Brengues)
• Biomarkers
of
hyper‐radiosensitive
patients
(D.
Azria)
Part
V
:
Perspectives
(3
h)
• Strategies
for
new
anticancer
drug
discovery
and
hit
identification
(N.
Guilbaud)
• Clinical
assessment
and
implication
of
biomarkers
identification:
from
early
targeted
clinical
treatment
to
daily
practice
(F
Barlési)
Part
VI
:
Methodoloy
in
Cancer
Research
(8
h)
L
Le
Cam
• Genetically
engineered
mouse
models
of
human
cancers
and
Humanized
models
(L.
Le
Cam)
• Training
session
on
small
animal
imaging
(SPECT‐CT,
Bioluminescence)
(M.
Busson)
• Training
session
on
anatomo‐pathological
analyses
of
mouse
models
(F.
Bernex)
Evaluation: 2 hrs. written exam (in English or in French)
Lecturers:
William
Jacot,
MD‐PhD,
Diego
Tosi,
MD‐PhD,
David
Azria,
MD‐PhD,
Céline
Bourgier
MD‐PhD
(ICM,
Institut
du
Cancer,
Montpellier)
Marie‐Alix
Poul,
PhD,
Celine
Gongora,
PhD,
Laurent
Le
Cam,
PhD,
Muriel
Busson,
PhD,
Bruno
Robert
PhD
(Cancer
Research
Institute,
Montpellier)
Florence
Bernex,
PhD
(Biocampus,
Montpellier)
Thierry
Maudelonde,
MD‐PhD
(CHU,
Montpellier)
Serge
Roche,
PhD
(CRBM,
Montpellier)
Alexandre
Evrard,
PharmD‐PhD
(CHU,
Nimes)
JM
Pascussi,
PhD
(Institute
of
Functional
Genetics,
IGF,
Montpellier)
Angelo
Constantinou,
PhD
(Institute
of
Human
Genetics,
IGH,
Montpellier)
Florence
Gattacceca,
Pharm‐D
PhD
(Faculty
of
Pharmacy,
Montpellier)
Fabrice
Barlesi,
MD‐PhD,
J
Ciccolini
MD
(APHM,
Univ.
de
la
Méditerranée,
Marseille)
Nicolas
Guilbaud
PhD
(Pierre
Fabre,
Toulouse)
Naomi
Taylor
MD‐PhD
,
Valérie
Dardhalon
PhD,
Franck
Mennechet
PhD
(IGMM,
Montpellier)
Guillaume
Cartron,
MD‐PhD
(CHU,
Montpellier)
Jean‐Paul
Brouillet,
Pharm‐D
PhD
(CHU,
Nimes)